Rigel’s High Science Bet
In an era in which biotechs focus on specialty drugs in niche populations, Rigel has been building a portfolio that looks different from other biopharmas in terms of what goes in and how it goes out. Although the company is currently valued on the performance of fostamatinib, investors might do well to take notice of Rigel’s pipeline.
You may also be interested in...
Arrowhead readies to advance its RNAi candidate for hepatitis B, while data on Achillion’s ‘3102 plus Sovaldi prepare the firm to start trials of its proprietary HCV combo. Coherus advances with a Humira biosimilar and Amgen will file Kyprolis for new indication despite failed study, while Rigel dry-eye failure has the firm refocusing on fostamatinib.
Dependent on revenues from AstraZeneca-partnered fostamatinib to fund its growth, Rigel has built a diverse and innovative portfolio. But disappointing results from a Phase IIb dose-ranging trial of fostamatinib – three other pivotal trials will report out soon – could signal trouble for the biopharma. Rigel execs Jim Gower and Raul Rodriguez share perspectives on the AstraZeneca deal and fostamatinib’s prospects.
Experts shared views at a recent conference in Seoul on how the Korean biopharma industry has evolved and what needs to be done to move forward in the next 10 years. Policy efficiency and family ownership in the sector came in for particular scrutiny, with some calling for sweeping changes.